(Q36849068)

16 August 2017

1 reference

title

Blockade of renin-angiotensin system in antifibrotic therapy (English)

1 reference

16 August 2017

Hitoshi Yoshiji

1

1 reference

16 August 2017

Shigeki Kuriyama

series ordinal

2

1 reference

16 August 2017

Hiroshi Fukui

series ordinal

3

1 reference

16 August 2017

publication date

1 June 2007

1 reference

Journal of Gastroenterology and Hepatology

16 August 2017

published in

1 reference

16 August 2017

volume

22 Suppl 1

1 reference

16 August 2017

page(s)

S93-5

1 reference

Biological functions of angiotensin and its receptors

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

Liver fibrosis -- from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

Adenovirus-mediated gene transfer of interferon α improves dimethylnitrosamine-induced liver cirrhosis in rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

Combination of interferon-beta and angiotensin-converting enzyme inhibitor, perindopril, attenuates the murine liver fibrosis development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

Fibrosis and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

VEGF: an update on biological and therapeutic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

Signaling via vascular endothelial growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

Vascular permeability factor (VPF, VEGF) in tumor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

Structure and function of VEGF/VEGF-receptor system involved in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

Vascular-specific growth factors and blood vessel formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

Perindopril: possible use in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

Host genetic factors influence disease progression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

Degradation of matrix proteins in liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2006.04663.X

10.1111/J.1440-1746.2006.04663.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference